Lead Product(s) : Limertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Innovent And Ask Pharm Collaborate on Limertinib For Lung Cancer Treatment
Details : Under the agreement, Innovent will obtain the exclusive commercialization rights for limertinib, a third-generation EGFR inhibitor for the treatment of lung cancer, in mainland China.
Brand Name : ASK120067
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 07, 2024
Lead Product(s) : Limertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
